Journal Article

DKFZ-2025-00304

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.

Liebers, N. (First author)DKFZ* ; Boumendil, A. ; Finel, H. ; Edelmann, D.DKFZ* ; Kobbe, G. ; Baermann, B.-N. ; Serroukh, Y. ; Blaise, D. ; Beelen, D. W. ; Solano, C. ; Itälä-Remes, M. ; van Meerten, T. ; Choi, G. ; Schmidt, S. A. C. ; Kröger, N. ; Byrne, J. ; Tudesq, J.-J. ; Ossami Saidy, A. ; Nunes, A. ; Siddiqi, R. ; Baro, E. ; Zheng, D. ; Kloos, I. ; Dreger, P. ; Sureda, A. ; Glass, B. ; Dietrich, S.

2025
American Association for Cancer Research Philadelphia, PA

This record in other databases:  

Please use a persistent id in citations: doi:10.1158/2643-3230.BCD-24-0178

Abstract: Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3% vs 59.2%, HR: 0.39, p=0.004) and lower non-relapse mortality (3.6% vs 21.2%, p=0.015) one year after treatment. Chronic graft-vs-host disease occurred in 26.9% of alloHCT patients within the first year. However, long-term progression-free survival and OS remain comparable. Despite limitations of this non-randomized study, it indicates a superior safety profile for brexu-cel in r/r MCL.

Note: #EA:B340# / 2025 May 5;6(3):182-190

---

Contributing Institute(s):

1. Translationale Medizinische Onkologie (B340)
2. C060 Biostatistik (C060)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2025

---

Database coverage:
; Clarivate Analytics Master Journal List ; Emerging Sources Citation Index ; IF >= 10 ; JCR ; SCOPUS ; Web of Science Core Collection

---